Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Post-marketing Safety Surveillance Program in HIV-infected Children Exposed to Atazanavir in Europe

The purpose of this study is to monitor adverse events in HIV-infected children <18 years old who are exposed to Atazanavir in a real-world setting in Europe.

Inclusion Criteria:

• HIV-infected children participating in individual prospective paediatric HIV cohorts
• Receive Atazanavir treatment during 01JAN2011 to 30DEC2013
• Age <18 years old on the date starting an Atazanavir-containing regimen
• Have a minimum of 3 months of follow-up